Publications by authors named "E J Koop"
Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the prognostic significance of BRCA1-related biomarkers in young, node-negative, chemotherapy-naïve triple-negative breast cancer (TNBC) patients, focusing on how these biomarkers influence overall survival outcomes.
- It included 485 Dutch women diagnosed with TNBC under age 40, assessing their BRCA1 status and tumor-infiltrating lymphocytes (sTILs) to determine outcomes over a 15-year period.
- Results showed that patients with pathogenic germline BRCA1 mutations had worse survival rates compared to those without alterations, but higher levels of sTILs significantly improved overall survival, particularly in patients with tumor BRCA1 promoter methylation.
Article Synopsis
- - This study examined the effectiveness of the PREDICT breast cancer prognostic model for young women under 40 with node-negative breast cancer who didn’t receive systemic treatment.
- - Researchers evaluated data from the Netherlands Cancer Registry and found that PREDICT significantly underestimated 10-year mortality rates and had moderate discrimination overall, especially poor for women with ER-negative tumors.
- - The findings suggest that PREDICT is not reliable for predicting outcomes in this specific group, emphasizing the need for updates to the model before it can be used routinely for young patients.
The classification of human epidermal growth factor receptor 2 (HER2) expression is optimized to detect HER2-amplified breast cancer (BC). However, novel HER2-targeting agents are also effective for BCs with low levels of HER2. This raises the question whether the current guidelines for HER2 testing are sufficiently reproducible to identify HER2-low BC.
View Article and Find Full Text PDFPurpose: Triple-negative breast cancer (TNBC) is considered aggressive, and therefore, virtually all young patients with TNBC receive (neo)adjuvant chemotherapy. Increased stromal tumor-infiltrating lymphocytes (sTILs) have been associated with a favorable prognosis in TNBC. However, whether this association holds for patients who are node-negative (N0), young (< 40 years), and chemotherapy-naïve, and thus can be used for chemotherapy de-escalation strategies, is unknown.
View Article and Find Full Text PDF